April 2009

Standardized Development Metrics

March 31, 2009

The use of standardized performance metrics by drug developers — CROs and sponsors — to reduce clinical development time and to improve deliverables is more essential than ever for success. BY ROBIN ROBINSON Many companies have attempted to come up with ways to better manage the clinical-trial process, but there has yet to be an […]

The Perils of Imprecise Forecasting

March 25, 2009

Contributed by Eric Levin, Senior VP, Princeton Brand Econometrics The ability to market products is directly related to how well a business can forecast outcomes based on alternative courses of action. Most pharmaceutical companies cannot do this very well. A forecaster whose science accurately accounts for a brand’s unique positioning, price, promotion, and competitive environment […]

Mission Possible: Transform the Clinical-Trial Process

March 25, 2009

The mission of the Clinical Trials Transformation Initiative (CTTI) is to identify practices that will increase the quality and efficiency of clinical trials. According to the organization, its first year was defined by great stakeholder enthusiasm, a strong organizational foundation, and rapid progress in a number of projects. The public/private partnership began in November 2007 […]

Dr. George Scangos: Gene Excellence

March 25, 2009

BY KIM RIBBINK With a practical approach to research and discovery, Dr. George Scangos has led Exelixis from a genomic research firm to a drug discovery and development company with expertise in oncology and metabolism. Research, by necessity, can often be an esoteric pursuit. But for George Scangos, Ph.D., the desire to base that research […]

Predicting the Future The Business Case for Forecasting

March 25, 2009

By Kim Ribbink Risk is an inherent part of the pharmaceutical business — risk of failure in clinical trials, risk that a product won’t achieve regulatory approval, risk that a product underperforms in the market, and risk of withdrawal after adverse reactions and the costly lawsuits that can follow. “Pressure from payers and competitors has […]

CMO: A Seat at the Agency Table

March 25, 2009

BY ROBIN ROBINSON The title of chief marketing officer or chief strategy officer has existed in other industries for years, and the position has been used with increasing frequency within larger consumer advertising agencies, but within the realm of pharmaceutical and healthcare advertising these titles are just starting to be embossed on the business cards […]

Last Word

March 25, 2009

Novartis Oncology’s David Epstein discusses the growing relevance of diagnostics in drug development. Mr. Epstein credits breakthroughs in biology and bioinformatics with an increased understanding of the genome that will enable developers to do a better job of matching the right drug with the right patient. As head of Novartis Oncology and the company’s new […]

Talent Pool

March 25, 2009

Pharmaceutical POOL Dr. Charles BOWDEN Peter TAM Vivus Announces Two Promotions Vivus, a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, has promoted two of its senior executives. Charles Bowden, M.D., has been promoted to senior director, clinical development, from director, clinical development. Dr. Bowden has assumed responsibility for Phase III […]

E-Media

March 25, 2009

New electronic and web-based applications, sites, and technologies Knexus Provides Business-to-Business Social Media Platform Knexus Tech has introduced a business-to-business (B2B) social media platform that gives companies a quick, easy way to engage busy business professionals with quality insights and rapid learning, as well as encourage social networking and interactions. Built on the Cloud Computing […]

What’s New

March 25, 2009

New healthcare-related products, services, and companies TGaS Advisors Offers Regulatory Service TGaS Advisors has launched the next generation of its Commercial Compliance Benchmark (CCB) to help companies navigate in a demanding and evolving regulatory environment. The new benchmark expands and enhances a previous offering from TGaS Advisors. Participating companies can expect to learn operational best […]

PharmaTrax

March 25, 2009

Sales, marketing, And R&D Trends affecting the healthcare industry Verified Physicians Ensure Quality Data As online physician panels gain popularity among pharmaceutical and medical device companies that conduct Web-based surveys, research shows there is little interest in verifying that the respondents in these surveys are indeed genuine physicians. This can severely impact the quality of […]

PharmaOutlet

March 25, 2009

Contributed by Kit Howard, M.S., CCDM, CRCP What makes professional certification valuable? In recent years, there has been a proliferation of certification programs within the pharma/biotech/devices world. Some are broad-based, such as project management (e.g., the Project Management Institute’s PMP). Others, for example, clinical monitoring and clinical data management, are industry-specific. Regardless of the profession, […]

UpFront

March 25, 2009

Investment Portfolio R&D Spending by U.S. Biopharmaceutical Companies Increases 3% in 2008 A new report reveals that R&D investment in new medicines by the biopharmaceutical industry was $65.2 billion in 2008, an increase of 3% from 2007, according to a combined analysis conducted by Burrill & Company and PhRMA. PhRMA-member companies alone spent about $50.3 […]

Letter from the Editor

March 25, 2009

Where do we go from here? There’s no getting away from it. It dominates the news. Everybody is talking about it. It, of course, is the economy. “Now, more than ever, in these economic times …” seems to be the theme of every news story (hard and soft), financial pundit, TV program, commercial, etc. There […]

FEEDBACK